[{"uuid": "8b2279b6-0114-3336-8ea6-ad102b28aaab", "title": "8MM Alzheimer's Disease Market Drug Forecast and Market Analysis 2023-2033: Eisai, Biogen, and Lilly are Forecast to Lead, Opportunities to Fulfil Key Unmet Needs, Novel Late-stage Pipeline Drugs", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/8mm-alzheimers-disease-market-drug-161900943.html", "providerPublishTime": 1738685940, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HP.E8HUfnyGeLtMAKwLgAQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc", "width": 480, "height": 58, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/KPtVInxraKsLNBMRw1U5aw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "3dd5f78f-c095-3cb2-95f8-896a489d96e8", "title": "Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/ardena-completes-acquisition-advanced-drug-130000426.html", "providerPublishTime": 1738674000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/CZGgPuiuxJBo8bvazXA8Wg--~B/aD0zNzgwO3c9NjcyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4ba2286930941c9100809eda0caccdb1", "width": 6720, "height": 3780, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/rRtatLO1iRRGDFiFePSC6w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4ba2286930941c9100809eda0caccdb1", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "1cdd3d35-e343-339c-a3f0-d1e78c9316d7", "title": "Zafrens Expands Investor Syndicate to Scale Revolutionary Drug Discovery Platform", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/zafrens-expands-investor-syndicate-scale-150400669.html", "providerPublishTime": 1738681440, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/0E.E68S2LvePMMvfOTk5Fg--~B/aD0zMjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/352e2c6d98e87584a52b1470504ea5d3", "width": 400, "height": 320, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/43YlH0dq2yjM1eWEj4RfPw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/352e2c6d98e87584a52b1470504ea5d3", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "f88cdd1a-77dd-3f40-89e8-17b9b5e335ec", "title": "Market Chatter: Novartis on Lookout for Next-Generation Obesity Drug Candidates", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/market-chatter-novartis-lookout-next-162250493.html", "providerPublishTime": 1738686170, "type": "STORY", "relatedTickers": ["NVS"]}, {"uuid": "7c79d163-4225-37a6-87a1-0ad1acb68554", "title": "Shionogi and Jordan\u2019s Guardian Angels Announce First-Ever Human Drug Study for Jordan\u2019s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/shionogi-jordan-guardian-angels-announce-133000136.html", "providerPublishTime": 1738675800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/wY81xBJ7RQueNAJS_DoGrQ--~B/aD00ODA7dz0zODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0bbe52b8fd7afb132e0985ee5f80de6d", "width": 385, "height": 480, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Z3a3fRBf3TsT6OwB7mrrjw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0bbe52b8fd7afb132e0985ee5f80de6d", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "5c3e1e1a-d0ff-304d-8e08-d356cf6a1e3e", "title": "Pluristyx Announces Filing of Drug Master File for PluriBank\u2122 iPSC Lines with U.S. FDA", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/pluristyx-announces-filing-drug-master-150700099.html", "providerPublishTime": 1738681620, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/11EP3XZaXIYAvm1p04gaaw--~B/aD0yMDk7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/96a2643aa1b0c6763ae5439e82767f72", "width": 983, "height": 209, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Ta6wQmxg42J0lFnnJrbS6A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/96a2643aa1b0c6763ae5439e82767f72", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "31176550-c76e-38f8-bd6b-6b4d99b56827", "title": "Zoetis Adds Warnings to Label for Dog-Pain Drug", "publisher": "The Wall Street Journal", "link": "https://finance.yahoo.com/m/31176550-c76e-38f8-bd6b-6b4d99b56827/zoetis-adds-warnings-to-label.html", "providerPublishTime": 1738683660, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Fwf5HL4GsEGPbDfR3MJBPg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8", "width": 1200, "height": 630, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zIJaagDuCJitt1Cvcwyc7A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ZTS"]}, {"uuid": "f9914d69-01c1-3e69-82e2-b9c6c1fe24f8", "title": "PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/pfes-colorectal-cancer-drug-meets-142600063.html", "providerPublishTime": 1738679160, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/IW5EhxEFuSd4V4nUFOhT_A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/AxvgHTECT_FnPZu0GsWG_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["PFE"]}, {"uuid": "7e6cbe86-a6b2-327d-856a-7899e86cdf51", "title": "CWENCH Hydration\u2122 Strengthens its Retail Footprint in Western Canada with Placement in 75 Locations of London Drugs", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/cwench-hydration-strengthens-retail-footprint-133000901.html", "providerPublishTime": 1738675800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/GFTm5kaPg6.q2_VAqRax3g--~B/aD0yNjI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3e41e6260b0f20a82033c100c2933c9c", "width": 480, "height": 262, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Xgq39rMUvbJLGxVZnuFTgw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3e41e6260b0f20a82033c100c2933c9c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CZZLF"]}, {"uuid": "e684fccf-bc86-389b-b19a-c763a9366a1e", "title": "Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend", "publisher": "Investor's Business Daily", "link": "https://finance.yahoo.com/m/e684fccf-bc86-389b-b19a-c763a9366a1e/regeneron-pharmaceuticals.html", "providerPublishTime": 1738685330, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/9BaGFiI3fyJlUr8bsJoxzw--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1", "width": 945, "height": 533, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6DXCRxfuMmhpbGiSjKqTZg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["REGN", "SNY", "SNYNF"]}, {"uuid": "e87a39b2-1dfa-3492-8e72-92249d3117a0", "title": "Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/northstrive-biosciences-inc-subsidiary-pmgc-130000839.html", "providerPublishTime": 1738674000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/v6QphQeBFH8UQf3pxkAy8w--~B/aD0xNjYyO3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/ec9820d47a83a7f25dde17cc45359068", "width": 2048, "height": 1662, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Cx6KM54T9WfAt8kwHwMPkg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ec9820d47a83a7f25dde17cc45359068", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ELAB"]}, {"uuid": "46b9fbd8-3589-3154-9652-5488f89b9449", "title": "FDA approves Roche\u2019s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/fda-approves-roche-susvimo-first-164500158.html", "providerPublishTime": 1738687500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/z0H6pXm3u9bqaZm6Rh4lrw--~B/aD01Mjk7dz04MDE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/84b0110bbf60eb8397db0461bc3549c4", "width": 801, "height": 529, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/YEYVwQ5wPaqEWQsgjuRKbA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/84b0110bbf60eb8397db0461bc3549c4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["RHHBF", "RHHBY", "RHHVF"]}, {"uuid": "eae1b954-9bfb-36dd-ae83-d6dfd656594d", "title": "IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/io-biotech-announces-publication-preclinical-130500718.html", "providerPublishTime": 1738674300, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/e9aeMH_kbCUT9OVLOHJMvQ--~B/aD0zNzt3PTE0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5d564c2b31691d2f6edccac46f996d38", "width": 148, "height": 37, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EXtICFL0KpCflAZyOnwaZg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5d564c2b31691d2f6edccac46f996d38", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["IOBT"]}, {"uuid": "19c97a3e-fee5-33ba-9121-fe7fac5165cc", "title": "Blue Cross Blue Shield of Massachusetts Publishes Positive Reimbursement Policy for the Nerivio\u00ae REN Wearable for Acute and Preventive Treatment of Migraine", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/blue-cross-blue-shield-massachusetts-131600244.html", "providerPublishTime": 1738674960, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RYCCcC6iSw0PIBvwQqSlqw--~B/aD0zNjk1O3c9NTU0MzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f683d6bc00b47470bb41397fc6bfe8e5", "width": 5543, "height": 3695, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1M3w6QeGuPsnS7.WLUuwrg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f683d6bc00b47470bb41397fc6bfe8e5", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "5c57cc32-9083-3ace-b361-19b27d14a3f3", "title": "FDA Approves Genentech\u2019s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/fda-approves-genentech-susvimo-first-164500154.html", "providerPublishTime": 1738687500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/PBQyk_9ADMD9mJpkewAYIw--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/182cac7492b551c3dde14e22840fd78d", "width": 480, "height": 480, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NglD6N7CUX96IJOKVf53xg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/182cac7492b551c3dde14e22840fd78d", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["RHHBF", "RHHBY", "RHHVF"]}, {"uuid": "99280fbf-a9cd-3bd4-bed5-9c30e83ac42b", "title": "MedPharm Appoints Bill Humphries as Chief Executive Officer to Lead Next Phase of Strategic Growth", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/medpharm-appoints-bill-humphries-chief-135600897.html", "providerPublishTime": 1738677360, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/A424QP943xj7iMd4Jqti5Q--~B/aD0zNzE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/16009323731a3e9baae5995cc720f934", "width": 400, "height": 371, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Bu_4KOUmHzMsgsT39NouNA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/16009323731a3e9baae5995cc720f934", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "d787a381-7da8-3dfb-9b05-780a880274ae", "title": "Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada", "publisher": "Newsfile", "link": "https://finance.yahoo.com/news/medexus-ontarios-provincial-health-services-120000545.html", "providerPublishTime": 1738670400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/CRX6pToj8xxCgZvsl7r2jg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/a647a713d3d5f69f93ab888f076ce971", "width": 400, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/3y7TXoGfIwWu9b1qQKGTGw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/newsfile_64/a647a713d3d5f69f93ab888f076ce971", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MEDXF"]}, {"uuid": "8669b6bc-5f79-39b6-a288-12b7d714e9a5", "title": "Neopharma Technologies and Impairment Science Strengthen Partnership to Revolutionize Drug and Impairment Testing", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/neopharma-technologies-impairment-science-strengthen-085900989.html", "providerPublishTime": 1738659540, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/qz5qn1dSemtzb6y6WwL2cw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4668691d9ba0bf92f3dae9711897e23b", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/I92ruufC_WJQlU7yhbrL9Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4668691d9ba0bf92f3dae9711897e23b", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "01e74c31-3f54-3c91-828b-1de73108228f", "title": "Laxxon Medical Announces Positive Pilot PK Study Results for Advanced Levodopa/Carbidopa Asset for Parkinson\u2019s Disease, LXM.5", "publisher": "ACCESS Newswire", "link": "https://finance.yahoo.com/news/laxxon-medical-announces-positive-pilot-140000325.html", "providerPublishTime": 1738677600, "type": "STORY"}, {"uuid": "fde86dd8-aafd-3f34-b8c8-2b323b3535db", "title": "Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/investors-seek-answers-novo-nordisks-061007042.html", "providerPublishTime": 1738649407, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/wT4W0oYU7l.TKowiCxAP8w--~B/aD01MjU7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/c7954da1c3a9f8499e1984e1cb085f22", "width": 800, "height": 525, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/devTXWnxDGTDozgv.3h1mA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/reuters-finance.com/c7954da1c3a9f8499e1984e1cb085f22", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["NVO", "LLY"]}]